DIANEAL PD-4 PERITONEAL DIALYSIS SOLUTION WITH 3.86 % GLUCOSE

Ülke: İsrail

Dil: İngilizce

Kaynak: Ministry of Health

şimdi satın al

Aktif bileşen:

CALCIUM CHLORIDE; GLUCOSE; GLUCOSE AS MONOHYDRATE; LACTIC ACID AS SODIUM; MAGNESIUM CHLORIDE; SODIUM CHLORIDE

Mevcut itibaren:

BAXTER HEALTHCARE DISTRIBUTION LTD., ISRAEL

ATC kodu:

B05DA

Farmasötik formu:

SOLUTION FOR PERITONEAL DIALYSIS

Kompozisyon:

GLUCOSE 38.6 G/L; LACTIC ACID AS SODIUM 4.5 G/L; GLUCOSE AS MONOHYDRATE 42.5 G/L; MAGNESIUM CHLORIDE 0.051 G/L; SODIUM CHLORIDE 5.4 G/L; CALCIUM CHLORIDE 0.184 G/L

Uygulama yolu:

PERITONEAL DIALYSIS

Reçete türü:

Required

Tarafından üretildi:

BAXTER HEALTHCARE S.A, IRELAND

Terapötik grubu:

ISOTONIC SOLUTIONS

Terapötik endikasyonlar:

Indicated whenever peritoneal dialysis is employed including acute and chronic renal failure, severe water retention, electrolyte disorders, drug intoxication.

Yetkilendirme tarihi:

2020-04-30

Bilgilendirme broşürü

                                لوانتت ة
ّ
رم
ّ
لك يف ة
ّ
يئاودلا ةعرجلا نمو ءاودلا ة
ّ
وبع ىلع قصلملا نم ق
ّ
قحت !ملاظلا يف ةيودلأا لوانت عنم
ُ
ي
.اهيلإ ةجاحب تنك اذإ ةي
ّ
بطلا تارا
ّ
ظنلا عض .ءاود اهيف
.
ّ
يلديصلا وأ بيبطلا ر
ِ
شتساف ءاودلا لامعتسا ىلإ ةبسنلاب ة
ّ
يفاضإ ةلئسأ كيدل تناك اذإ
4 .
ةيبناجلا ضارعلأا
ةءارق دنع مدصت لا .نيمدختسملا نم مسق
ىدل ة
ّ
يبناج ا
ً
ضارعأ PD4 لينايد لامعتسا ب
ّ
بسي دق ،ةيودلأا عيمجك
.اهنم
ٍ
ّ
يأ نم يناعت
ّ
لاأ لمتحملا نم .ة
ّ
يبناجلا ضارعلأا ةمئاق
:ةيلاتلا ةيبناجلا ضارعلأا ىدحإ نم
يناعت تنك اذإ نكمي ام عرسأب ةيقافصلا
ازيلايدلا زكرم وأ بيبطلا غلابإ بجي

داتعملا نم رثكأ عفترم مد طغض

ردصلا يف ملاآ وأ سفنت قيض ،نينيعلا لوح
خافتنا ،نيقاسلا وأ نيلحاكلا يف خافتنا

)نوسنوج زنفيتس ةمزلاتم( ةيلسانتلا
ءاضعلأاو نينيعلا ،مفلا ،دلجلا ىلع
تلاصيوح عم بعص ضرم

نطبلا يف ملاآ

ةنوخس

]peritonitis[ يقافص باهتلا
.ئراط
ّ
يبط جلاع ىلإ جاتحت نأ لمتحملا نم .ةريطخ
ضارعأك ضارعلأا هذه لك ربتعت :ة
ّ
يفاضإ ةيبناج ضارعأ
:PD4 لينايدب نيجلاعت
ُ
ملا نم فورعم ريغ ددع ىدل اهنع غيلبتلا
ّ
مت يتلا ة
ّ
يبناجلا ضارعلإا

:مدلا يف تارييغت
o
ىلإ يدؤي نأ نكمم يذلا )hypokalemia – مدلا
مويساتوب صقن( مويساتوبلا تايوتسم يف
ضافخنا
مظتنم ريغ ضبن وأ تاجنشت ،تلاضع فعض
o
،بعت ىلإ يدؤي دق ي
                                
                                Belgenin tamamını okuyun
                                
                            

Ürün özellikleri

                                SUMMARY OF PRODUCT CHARACTERISTICS
Dianeal PD4 Peritoneal Dialysis Solution with 1.36% Glucose
Dianeal PD4 Peritoneal Dialysis Solution with 2.27% Glucose
Dianeal PD4 Peritoneal Dialysis Solution with 3.86% Glucose
1.
NAME OF THE MEDICINAL PRODUCT
Dianeal PD4 Peritoneal Dialysis Solution with 1.36% Glucose
Dianeal PD4 Peritoneal Dialysis Solution with 2.27% Glucose
Dianeal PD4 Peritoneal Dialysis Solution with 3.86% Glucose
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_DIANEAL PD4 PERITONEAL DIALYSIS SOLUTION WITH 1.36% W/V GLUCOSE _
Glucose (as monohydrate)
Ph.Eur.
1.36% w/v
Sodium Chloride
Ph.Eur.
0.538% w/v
Sodium Lactate
Ph.Fr. + internal specification
0.448% w/v
Calcium Chloride
Ph.Eur.
0.0184% w/v
Magnesium Chloride
Ph.Eur.
0.0051% w/v
_DIANEAL PD4 PERITONEAL DIALYSIS SOLUTION WITH 2.27% W/V GLUCOSE _
Glucose (as monohydrate)
Ph.Eur.
2.27% w/v
Sodium Chloride
Ph.Eur.
0.538% w/v
Sodium Lactate
Ph.Fr. + internal specification
0.448% w/v
Calcium Chloride
Ph.Eur.
0.0184% w/v
Magnesium Chloride
Ph.Eur.
0.0051% w/v
_DIANEAL PD4 PERITONEAL DIALYSIS SOLUTION WITH 3.86% W/V GLUCOSE _
Glucose (as monohydrate)
Ph.Eur.
3.86% w/v
Sodium Chloride
Ph.Eur.
0.538% w/v
Sodium Lactate
Ph.Fr. + internal specification
0.448% w/v
Calcium Chloride
Ph.Eur.
0.0184% w/v
Magnesium Chloride
Ph.Eur.
0.0051% w/v
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for peritoneal dialysis.
Clear solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Dianeal PD4 is indicated whenever peritoneal dialysis is employed,
including:
1.
Acute and chronic renal failure;
2.
Severe water retention;
3.
Electrolyte disorders;
4.
Drug intoxication.
Route of administration
Intraperitoneal administration only.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_Posology: _
The mode of therapy, frequency of treatment, exchange volume, duration
of dwell and
length of dialysis should be selected by the attending physician.
Adults
Patients on continuous ambulatory peritoneal dialysis (CAPD) typically
perform 4
cycles per day (24 hour
                                
                                Belgenin tamamını okuyun
                                
                            

Diğer dillerdeki belgeler

Bilgilendirme broşürü Bilgilendirme broşürü Arapça 12-05-2020
Bilgilendirme broşürü Bilgilendirme broşürü İbranice 18-09-2022